Myriad Genetics
MYGN
#3912
Rank
NZ$4.05 B
Marketcap
$44.68
Share price
-2.30%
Change (1 day)
55.90%
Change (1 year)

P/E ratio for Myriad Genetics (MYGN)

P/E ratio as of September 2024 (TTM): -9.19

According to Myriad Genetics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -9.19408. At the end of 2022 the company had a P/E ratio of -10.4.

P/E ratio history for Myriad Genetics from 2001 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-10.4-86.01%
2021-74.61062.12%
2020-6.42-91.51%
2019-75.6-198.87%
201876.5320.92%
201718.2-2.97%
201618.7-39.68%
201531.136.75%
201422.7158.67%
20138.78-51.68%
201218.27.58%
201116.92.77%
201016.4-23.79%
200921.6-29.71%
200830.7-140.31%
2007-76.1157.71%
2006-29.564.68%
2005-17.913.91%
2004-15.743.21%
2003-11.0-29.99%
2002-15.7-90.75%
2001-170

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
-58.2 532.86%๐Ÿ‡บ๐Ÿ‡ธ USA
-44.4 382.57%๐Ÿ‡บ๐Ÿ‡ธ USA
-0.0085-99.91%๐Ÿ‡บ๐Ÿ‡ธ USA
90.6-1,085.88%๐Ÿ‡บ๐Ÿ‡ธ USA
38.4-517.69%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.